MARKET OUTLOOK
The Europe immunohistochemistry market is projected to develop at a CAGR of 7.06% during the forecast period of 2019-2027.
Countries such as the United Kingdom, Germany, France, Italy, Spain, Russia as well as countries in rest of Europe have considered for this report.
The Germany immunohistochemistry market is mainly driven by the constant rise in the prevalence of CVDs in the country. According to the Organization for Economic Co-operation and Development (OECD), Germany has one of the highest death rates owing to heart disease in the OECD group of countries that is even higher than the United Kingdom and the United States. According to the Max Planck Institute for Biology and Aging, heart disorders are a major cause of death in the country. These heart disorders mainly include heart attacks, strokes and high blood pressure. There are various causes considering cardiovascular diseases that include genetics & natural aging and obesity & overweight, but smoking and high cholesterol can increase the risk on a large scale. Germany has a high prevalence of diabetes, which is also further augmenting the growth of the immunohistochemistry market in the country.
COMPETITIVE OUTLOOK
The companies leading the immunohistochemistry market are F. Hoffmann-La Roche AG, Abcam Plc, Agilent Technologies, Inc., Danaher Corporation, Histologix, Thermo Fisher Scientific, Inc., Cell Signaling Technology, Inc., Bio SB, Siemens AG Healthcare, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., BioGenex, Merck Millipore and Abbott Laboratories.